A study reported CAR-T cells engineered to target both mesothelin (a cancer-related antigen) and fibroblast activation protein (FAP) which effectively promotes the elimination of PC cells and cancer-associated fibroblasts in various patient-derived models, showing promise as a treatment option for immunotherapy-resistant solid tumours (100). The gene discussed is MSLN; the disease is cancer.